On November 27th, as part of OBIO's Annual Public Meeting, OBIO will be launching our latest report, Bridging the Talent Gap, on the unique value of OBIO’s Health to Business Bridge (H2BB™) business internship program in 2017.
Ontario has appointed Dr. Molly Shoichet as the province's first Chief Scientist with a mandate to advance science and innovation in Ontario. The new Office of the Chief Scientist will report to Reza Moridi, Minister of Research, Innovation and Science.
Dr. Shoichet is a professor at the University of Toronto, a member of the Order of Ontario, and founder of Hammock Therapeutics, an OBIO CAAP company.
The Centre for the Commercialization of Antibodies and Biologics (CCAB) Board of Directors is pleased to announce the appointment of Mr. Robert Verhagen as the organization’s new Chief Executive Officer, effective November 1, 2017.
As CCAB’s new CEO, Mr. Verhagen will provide his strategic direction to position CCAB as a leader in the commercialization of academic discoveries in the biologics field and in the advancement of this biotech sector in Canada.
2015 CAAP Company Conavi Medical Inc., a privately-held company developing image guidance technologies for minimally invasive procedures announced that it has entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of its ForesightTM Intracardiac Echocardiography (ICE) and NovasightTM Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan and Macau.
Application Deadline January 10, 2018 - Apply Here
The Canadian Technology Accelerator Initiative (CTA) helps high-potential, high-growth Canadian technology SMEs seeking to expand to the U.S through a 5 month program of workshops, events, mentorship and business introductions.